AR004671A1 - Nuevos compuestos en calidad de kappa-opiatagonistas y composiciones farmaceuticas que los contienen - Google Patents
Nuevos compuestos en calidad de kappa-opiatagonistas y composiciones farmaceuticas que los contienenInfo
- Publication number
- AR004671A1 AR004671A1 ARP960103374A AR10337496A AR004671A1 AR 004671 A1 AR004671 A1 AR 004671A1 AR P960103374 A ARP960103374 A AR P960103374A AR 10337496 A AR10337496 A AR 10337496A AR 004671 A1 AR004671 A1 AR 004671A1
- Authority
- AR
- Argentina
- Prior art keywords
- signifies
- hal
- compounds
- treating
- nhcoa
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Compuestos de formula (I) en la que R1 significa Ar, cicloalquilo de 3 a 7 atomos de C o cicloalquilalquilo de 4 a 8 atomos de C; R2 significa Ar, ytambien R1 junto con R2 representan formula (II); R3 significa H, OH, OA o A; R4 significa A ofeni lo eventualmente sustituido una o dos veces con Hal, OH,OA, CF3, NO2, NH2, NHA, NHCOA, NHSO2A o NA2; R5 significa OH o CH2OH; R6 y R7, independientemente significan H, Hal, OH, OA, CF3, NH2, NHA, NA2, NHCOA,NHCONH2, NO2 o metilendioxi; Asignifica a lquilo de 1 a 7 atomos deC; Ar significa un resto aromatico mono o biciclico, en el cual un atomo de C puedeestar sustituido por un heteroatomo de N o u S y que puede estar sustituido una, dos o tres veces con A, Hal, OH, OA,CF3, NH2, NHA , NA2, NHCOA y/oNHCONH2; D equivale a CH2, O, S, NH, NA, -CH2-CH2-, -CH=CH-, -CH2-NH-, CH2-NA- o una ligadura, y Hal significa F, Cl, Br o I; excepto el clorhidrato deN-metil-N-[(1S)-1-fenil-2-((3S)-3-hidroxipirrolidina-1-il)-etil]-2,2-difenil- acetamida y las composiciones farmaceuticas que los contienen. Los compuestosson apropiados para tratar enfermedades inflamatorias del intestino y los sintomas deenfermedad, asociadas a ellas, y tambien para tratar los doloresintensos, en par ticular la hipersensibilidad a los dolores que se presentan en los padecimientos de la zona dorsal, quemaduras, quemaduras solares yenfermedades reumaticas, y lasreacciones inflamatorias concomitantes. Estos compuestos tambien son apropiados par a tratar los dolores post-operatorios, elilio (oclusion intestinal) que se presenta a menudo despues de las operaciones abdominales, y para tratar laneurodermatitis.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19523502A DE19523502A1 (de) | 1995-06-28 | 1995-06-28 | Kappa-Opiatagonisten für entzündliche Darmerkrankungen |
Publications (1)
Publication Number | Publication Date |
---|---|
AR004671A1 true AR004671A1 (es) | 1999-03-10 |
Family
ID=7765475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP960103374A AR004671A1 (es) | 1995-06-28 | 1996-06-28 | Nuevos compuestos en calidad de kappa-opiatagonistas y composiciones farmaceuticas que los contienen |
Country Status (26)
Country | Link |
---|---|
US (2) | US5776972A (es) |
EP (1) | EP0752246B1 (es) |
JP (2) | JP4415075B2 (es) |
KR (1) | KR100501612B1 (es) |
CN (1) | CN1119147C (es) |
AR (1) | AR004671A1 (es) |
AT (1) | ATE214275T1 (es) |
AU (1) | AU708699B2 (es) |
BR (1) | BR9602915A (es) |
CA (1) | CA2179955C (es) |
CO (1) | CO4700454A1 (es) |
CZ (1) | CZ289805B6 (es) |
DE (2) | DE19523502A1 (es) |
DK (1) | DK0752246T3 (es) |
ES (1) | ES2171577T3 (es) |
HU (1) | HU226976B1 (es) |
NO (1) | NO309674B1 (es) |
PL (1) | PL185537B1 (es) |
PT (1) | PT752246E (es) |
RU (1) | RU2190401C2 (es) |
SI (1) | SI0752246T1 (es) |
SK (1) | SK283497B6 (es) |
TR (1) | TR199600497A2 (es) |
TW (1) | TW430557B (es) |
UA (1) | UA51615C2 (es) |
ZA (1) | ZA965480B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763445A (en) | 1996-03-08 | 1998-06-09 | Adolor Corporation | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
US6239154B1 (en) | 1996-03-08 | 2001-05-29 | Adolor Corporation | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
US6303611B1 (en) * | 1996-03-08 | 2001-10-16 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
DE69720518T2 (de) * | 1996-12-02 | 2004-02-26 | Kyorin Pharmaceutical Co., Ltd. | Neue derivate von n-substituierten pyrrolidin derivaten und deren herstellungsverfahren |
US6133307A (en) * | 1997-04-30 | 2000-10-17 | Warner-Lambert Company | Certain benzofuranyl-N-[pyrrolidin-1-YL]-N-methyl-acetamide derivatives useful as opioid agonists |
JP2003526594A (ja) * | 1997-07-14 | 2003-09-09 | アドラー コーポレーション | カッパ・アゴニスト抗掻痒薬学的製剤およびそれにより掻痒を治療する方法 |
US5760023A (en) * | 1997-07-14 | 1998-06-02 | Adolor Corporation | Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith |
DE19827633A1 (de) * | 1998-04-20 | 1999-10-21 | Merck Patent Gmbh | Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid |
DE10116978A1 (de) * | 2001-04-05 | 2002-10-10 | Merck Patent Gmbh | Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase |
BR0309969A (pt) | 2002-05-17 | 2005-04-26 | Merck Patent Gmbh | Uso de compostos que são eficazes como moduladores de receptores seletivos de opiáceos |
AU2003269399A1 (en) * | 2002-11-01 | 2004-05-25 | Pfizer Products Inc. | Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination |
DE10259245A1 (de) | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Derivate des Asimadolins mit kovalent gebundenen Säuren |
EP1642590A4 (en) * | 2003-07-04 | 2009-05-13 | Santen Pharmaceutical Co Ltd | MEANS TO INHIBIT THE DEGRADATION OF THE PAIN LIMIT |
WO2005046687A1 (en) * | 2003-10-30 | 2005-05-26 | Tioga Pharmaceuticals, Inc. | Use of selective opiate receptor modulators in the treatment of neuropathy |
US7160902B2 (en) * | 2003-11-14 | 2007-01-09 | Adolor Corporation | Amide derivatives and methods of their use |
US7642274B2 (en) | 2004-07-02 | 2010-01-05 | Santen Pharmaceutical Co., Ltd. | Inhibitor of pain threshold decrease |
CN101677997B (zh) * | 2007-03-30 | 2012-05-09 | 泰奥加制药公司 | 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂 |
KR101773331B1 (ko) | 2012-03-05 | 2017-08-31 | 닥터 레디스 레보러터리즈 리미티드 | 카파 오피오이드 수용체(κor) 작용제인 치환된 헤테로시클릭 아세트아미드 |
EA201691489A1 (ru) * | 2014-01-24 | 2016-12-30 | Кадила Хелзкэр Лимитед | Новые гетероциклические соединения в качестве агонистов каппа-опиодиов |
EP3558300B1 (en) | 2016-12-21 | 2021-11-24 | Tioga Pharmaceuticals, Inc. | Solid pharmaceutical formulations of asimadoline |
WO2019122361A1 (en) | 2017-12-22 | 2019-06-27 | Dr. August Wolff Gmbh & Co. Kg Arzneimittel | Asimadoline for use in treating pulmonary diseases, vascular diseases, and sepsis |
EP3932390A1 (en) | 2020-07-02 | 2022-01-05 | Dr. August Wolff GmbH & Co. KG Arzneimittel | Topical gel formulation containing asimadoline |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4663343A (en) * | 1985-07-19 | 1987-05-05 | Warner-Lambert Company | Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds |
DE4034785A1 (de) * | 1990-11-02 | 1992-05-07 | Merck Patent Gmbh | 1-(2-arylethyl)-pyrrolidine |
US5232978A (en) * | 1988-12-23 | 1993-08-03 | Merck Patent Gesellschaft Mit Beschrankter Haftung | 1-(2-arylethyl)-pyrrolidines |
US5232266A (en) * | 1989-07-24 | 1993-08-03 | Mork William J | Upholstered article of furniture with interchangeable seating module |
DE4215213A1 (de) * | 1992-05-09 | 1993-11-11 | Merck Patent Gmbh | Arylacetamide |
-
1995
- 1995-06-28 DE DE19523502A patent/DE19523502A1/de not_active Withdrawn
-
1996
- 1996-06-12 TR TR96/00497A patent/TR199600497A2/xx unknown
- 1996-06-20 ES ES96109915T patent/ES2171577T3/es not_active Expired - Lifetime
- 1996-06-20 SI SI9630475T patent/SI0752246T1/xx unknown
- 1996-06-20 DE DE59608861T patent/DE59608861D1/de not_active Expired - Lifetime
- 1996-06-20 PT PT96109915T patent/PT752246E/pt unknown
- 1996-06-20 EP EP96109915A patent/EP0752246B1/de not_active Expired - Lifetime
- 1996-06-20 AT AT96109915T patent/ATE214275T1/de active
- 1996-06-20 DK DK96109915T patent/DK0752246T3/da active
- 1996-06-24 AU AU56162/96A patent/AU708699B2/en not_active Ceased
- 1996-06-25 CZ CZ19961866A patent/CZ289805B6/cs not_active IP Right Cessation
- 1996-06-26 JP JP16598896A patent/JP4415075B2/ja not_active Expired - Fee Related
- 1996-06-26 CA CA002179955A patent/CA2179955C/en not_active Expired - Fee Related
- 1996-06-26 RU RU96112771/14A patent/RU2190401C2/ru not_active IP Right Cessation
- 1996-06-27 CN CN96110142A patent/CN1119147C/zh not_active Expired - Fee Related
- 1996-06-27 NO NO962720A patent/NO309674B1/no unknown
- 1996-06-27 TW TW085107762A patent/TW430557B/zh not_active IP Right Cessation
- 1996-06-27 UA UA96062557A patent/UA51615C2/uk unknown
- 1996-06-27 ZA ZA965480A patent/ZA965480B/xx unknown
- 1996-06-27 BR BR9602915A patent/BR9602915A/pt not_active Application Discontinuation
- 1996-06-27 KR KR1019960024568A patent/KR100501612B1/ko not_active IP Right Cessation
- 1996-06-27 PL PL96314996A patent/PL185537B1/pl not_active IP Right Cessation
- 1996-06-27 SK SK843-96A patent/SK283497B6/sk not_active IP Right Cessation
- 1996-06-27 US US08/671,502 patent/US5776972A/en not_active Expired - Lifetime
- 1996-06-28 CO CO96034158A patent/CO4700454A1/es unknown
- 1996-06-28 HU HU9601798A patent/HU226976B1/hu not_active IP Right Cessation
- 1996-06-28 AR ARP960103374A patent/AR004671A1/es not_active Application Discontinuation
-
1998
- 1998-02-20 US US09/027,228 patent/US5977161A/en not_active Expired - Lifetime
-
2008
- 2008-04-23 JP JP2008112917A patent/JP5308056B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR004671A1 (es) | Nuevos compuestos en calidad de kappa-opiatagonistas y composiciones farmaceuticas que los contienen | |
AR021844A1 (es) | Derivados de propanolamina aril-sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su utilizacion | |
EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
CR6881A (es) | Derivados de pirazol | |
BR0206955A (pt) | Ligantes de receptores de canabinóides | |
ES2137991T3 (es) | Eniantinas y derivados de eniantina para la lucha contra los endoparasitos. | |
CY1110977T1 (el) | Υποκατεστημενα παραγωγα ινδολης για φαρμακευτικη συνθεση για θεραπεια ασθενειων του αναπνευστικου | |
AR028985A1 (es) | Compuestos derivados de quinolin-2-ona- sustituidos con heteroarilo utiles como agentes anticancerigenos, procedimiento de tratamiento de enfermedades utilizando dicho compuesto, composicion farmaceutica que lo contiene | |
EA200500174A1 (ru) | Новые производные бензимидазола, полезные в качестве антипролиферативных агентов | |
BR9713186A (pt) | Inibidores de metaloprotease 1,3-diheterocìclicos | |
CR20120007A (es) | 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728) | |
AR028810A1 (es) | Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion | |
EA200601802A1 (ru) | Производные морфолина | |
CO5180642A1 (es) | Compuestos sustituidos de piperidina, procesos para su prepa racion, composiciones farmaceuticas que los contienen y su utilizacion | |
AR036596A1 (es) | Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonista de cb1 | |
ES2161291T3 (es) | N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa. | |
PE20050130A1 (es) | Compuestos organicos | |
MX9305056A (es) | Composicion reguladora de apoptosis. | |
BR9811774A (pt) | Tetraidroprostaglandinas aromáticas substituìdas por c16-c20 úteis como agonistas fp | |
PA8582701A1 (es) | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf) | |
TR200000673T2 (tr) | FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler. | |
MX9306311A (es) | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
MX9305947A (es) | Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen. | |
AR004158A1 (es) | Compuesto de ftalizin-pirido dionas; composición farmacéutica que lo contiene; y proceso para la preparación de dicho compuesto. | |
AR007098A1 (es) | Inhibidores de la metaloproteasa de matriz, composiciones que los comprenden, y uso de los mismos para preparar composiciones farmaceuticas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |